Medical-device company Invenio Imaging is at the forefront of a technological breakthrough. They are developing a system that allows surgeons to instantly evaluate tissue biopsies in the operating room. With the help of AI, surgeons can gain insights in just three minutes, a process that traditionally could take weeks in a pathology lab. This rapid evaluation aids in immediate clinical decision-making, especially during surgeries or biopsies. Chris Freudiger, the CTO of Invenio, highlighted that this technology would enable surgeons to quickly determine if a tissue sample contains cancerous cells and make decisions on the spot.
Invenio’s innovation doesn’t stop there. Their NIO Laser Imaging System, a digital pathology tool, has already been used in numerous procedures across the U.S. and Europe. This system is set to be enhanced with NVIDIA’s Jetson Orin series of edge AI modules, aiming to provide near real-time AI inference. Furthermore, Invenio is collaborating with Johnson & Johnson’s Lung Cancer Initiative to develop an AI solution for evaluating lung biopsies, given that lung cancer is the deadliest form of cancer worldwide.
- Rapid Decision Making in Surgery: The ability to evaluate tissue samples within minutes can revolutionize surgical procedures, especially when dealing with aggressive cancers. How might this impact the overall success rate of surgeries?
- AI in Healthcare: With AI being integrated into medical devices and procedures, what other areas of healthcare might benefit from such advancements?
- Collaborations for Innovation: Invenio’s collaboration with Johnson & Johnson showcases the potential of combining expertise. How might other industries benefit from similar collaborative efforts?